Fmr LLC Boosts Stock Position in Turnstone Biologics Corp. (NASDAQ:TSBX)

Fmr LLC increased its stake in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) by 3.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,172,987 shares of the company’s stock after buying an additional 37,738 shares during the quarter. Fmr LLC owned about 5.07% of Turnstone Biologics worth $653,000 at the end of the most recent reporting period.

Separately, Sei Investments Co. purchased a new position in shares of Turnstone Biologics during the 2nd quarter worth $31,000. 52.51% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Bank of America lowered shares of Turnstone Biologics from a “neutral” rating to an “underperform” rating in a report on Friday, November 15th.

Turnstone Biologics Stock Performance

Shares of Turnstone Biologics stock opened at $0.50 on Wednesday. The stock has a 50 day moving average of $0.50 and a 200 day moving average of $1.30. The firm has a market capitalization of $11.61 million, a price-to-earnings ratio of -0.15 and a beta of 2.44. Turnstone Biologics Corp. has a fifty-two week low of $0.40 and a fifty-two week high of $5.75.

Turnstone Biologics (NASDAQ:TSBX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.13. Analysts forecast that Turnstone Biologics Corp. will post -3.75 EPS for the current year.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.